EXEL
USDExelixis Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$37.810
最高
$38.900
最低
$37.582
交易量
2.81M
公司基本面
市值
10.2B
行業
生物科技
國家
United States
交易統計
平均交易量
2.62M
交易所
NMS
貨幣
USD
52週範圍
相關新聞
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for
Guggenheim Downgrades Exelixis to Neutral
Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.
RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target
RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.
Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30
Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.
